The effectiveness of magnesium sulfate vaginal gel on cervical ripening and induction of labor in nulliparous women

The effectiveness of magnesium sulfate vaginal gel on cervical ripening and induction of labor in nulliparous women: a randomized controlled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210105049944N1

Enrollment

174

Registered

2021-03-06

Start date

2021-04-19

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical ripening and induction of labor.

Interventions

Intervention 1: Intervention group: The first group receives magnesium sulfate vaginal gel containing 6 grams of magnesium sulfate prepared by the Industrial Laboratory of the Faculty of Pharmacy, Ahv

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Desire to participate in the study Being nulliparous Mother age 18-40 years Body mass index 18.5-25 Post date gestational age Bishop score less than 4 Single fetus with cephalic presentation and intact membranes Estimated weight of the fetus 2500-4000 grams Low risk pregnancy Indication of labor induction

Exclusion criteria

Exclusion criteria: Risky underlying disease (anemia, blood disorders, heart or lung disease, connective tissue and smooth muscle problems) History of any uterine scar Refer with bleeding or rupture of membranes Multiple pregnancy Diagnosis of cephalopelvic disproportion by a physician Contraindications to use of magnesium sulfate Patient non-cooperation

Design outcomes

Primary

Measure	Time frame
Average of Bishop score. Timepoint: Before the intervention, 4 hours after the intervention, 8 hours after the intervention. Method of measurement: Vaginal examination, Bishop score table.	—

Secondary

Measure	Time frame
The length of labor. Timepoint: End of the study. Method of measurement: Partograph form.;Probable complications of magnesium sulfate. Timepoint: 4 hours after the start of the intervention, 8 hours after the start of the intervention. Method of measurement: Questionnaire.;Number of doses of misoprostol used. Timepoint: End of the study. Method of measurement: Hospital file.;Type of delivery. Timepoint: End of the study. Method of measurement: Hospital file.;Number of doses of oxytocin used. Timepoint: End of the study. Method of measurement: Hospital file.;Duration of hospitalization of mother. Timepoint: End of the study. Method of measurement: Hospital file.;APGAR score of the first and fifth minutes. Timepoint: End of the study. Method of measurement: Hospital file.	—

Measure

Time frame

The length of labor. Timepoint: End of the study. Method of measurement: Partograph form.;Probable complications of magnesium sulfate. Timepoint: 4 hours after the start of the intervention, 8 hours after the start of the intervention. Method of measurement: Questionnaire.;Number of doses of misoprostol used. Timepoint: End of the study. Method of measurement: Hospital file.;Type of delivery. Timepoint: End of the study. Method of measurement: Hospital file.;Number of doses of oxytocin used. Timepoint: End of the study. Method of measurement: Hospital file.;Duration of hospitalization of mother. Timepoint: End of the study. Method of measurement: Hospital file.;APGAR score of the first and fifth minutes. Timepoint: End of the study. Method of measurement: Hospital file.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Chenari

Ahvaz University of Medical Sciences

chenari.z@ajums.ac.ir+98 61 3373 8331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026